Want to see SE:ATORX full AI Analyst Report?
ATORX Stock Chart & Stats
kr0.05
>-kr0.01(-8.19%)
At close: 4:00 PM EDT
kr0.05
>-kr0.01(-8.19%)
Day’s Range― - ―
52-Week Rangekr0.03 - kr1.57
Previous CloseN/A
Volume25.04M
Average Volume (3M)1.75M
Market Cap
kr22.88M
Enterprise Valuekr93.66
Total Cash (Recent Filing)kr32.98M
Total Debt (Recent Filing)kr32.38M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding534,516,970
10 Day Avg. Volume1,169,449
30 Day Avg. Volume1,745,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet And Lower LeverageLower leverage and rebuilt positive equity materially improve financial flexibility for a clinical-stage biotech. This reduces insolvency risk, supports continued R&D funding or partner negotiations, and makes future financing or licensing deals easier to structure over the next several quarters.
Partnering/licensing-focused Business ModelA partnership-centric model conserves capital versus building commercial infrastructure, lets larger partners fund late-stage development and commercialization, and creates milestone-driven cash inflows that can de-risk the balance sheet long-term if programs progress or deals are signed.
Focus On Antibody-based Immunotherapies In OncologyConcentrating on immuno-oncology aligns with a durable, high-priority area of drug development where strategic partnerships and licensing interest are strong. A focused pipeline in antibodies and immunomodulation increases the chance of program-level deals or co-development options.
Bears Say
Large Negative Operating And Free Cash FlowSustained, large cash burn implies ongoing external financing or dilutive capital raises. That constrains strategic optionality, pressures management to prioritize near-term financing over long-term R&D choices, and elevates execution risk if funding conditions tighten over the next several quarters.
Sharp Revenue Decline And Minimal Current RevenueA severe revenue decline reduces operating resilience and signals either ended partnerships or lumpy milestone timing. Low recurring income weakens bargaining power with partners, increases dependency on financing, and makes short- to medium-term sustainability contingent on new deals or milestone receipts.
Persistent Deep Losses And Negative MarginsOngoing large operating losses erode retained capital and have historically pressured equity levels. Until a program is partnered or revenues scale, persistent unprofitability raises dilution risk, limits strategic options, and makes long-term viability dependent on external funding or successful licensing events.
Alligator Bioscience AB News
ATORX FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest stock price was kr0.03 and its highest was kr1.57 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr22.88M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is Aug 27, 2026 which is in 21 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on May 05, 2026. The company reported kr0.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 534,516,970 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of kr0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.469%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in SE:ATORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Technical Analysis
Alzinova AB
―
Nanologica AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
NextCell Pharma AB
―